TCR2 Therapeutics, Inc. announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo® and Yervoy® in its planned Phase II clinical trial in treatment refractory mesothelin-expressing solid tumors.
[TCR2 Therapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.
